The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer

• Status: Completed
• Trial end date: 2002-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this trial was to select a dose of degarelix (FE 200486). Three groups of patients were treated for six months on different doses. The patients had blood samples taken and measured for Testosterone in order to determine the most efficient dose to provide fast and sustained castration. The patients came to the clinic for 16 visits and dependent on the blood sample results they were invited to return for additional blood samples on a two weekly basis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals

Criteria

Inclusion Criteria:

• Signed informed consent before any trial related activity

• Proven prostate cancer with a need for endocrine treatment

• Testosterone level within the normal range for the age

Exclusion Criteria:

• Previous or current hormonal treatment of prostate cancer

• Candidate for prostatectomy or radiotherapy

• History of severe asthma, anaphylactic reactions or Quincke's Oedema

• Hypersensitivity towards any component of FE200486

• Cancer disease within the last ten years except for prostate cancer and some skin cancers

• Presenting with significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, haematological, dermatological or infectious disorder. In addition any other condition such as excessive alcohol or drug abuse that may interfere with trial participation or influence the conclusion of the trial as judged by the investigator

• Mental incapacity or language barrier

• Having received an investigational product within the last 12 weeks preceding the trial

• Previous participation in this trial